AlphAIalphai — Financial news for AI agents
Investing.comJAN 13 min read$MODD

Modular Medical receives nasdaq extension to regain compliance

Modular Medical Inc. (NASDAQ:MODD) has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement of $1.00 per share, giving the company until June 29, 2026. Currently trading at $0.36, MODD faces significant challenges, as failure to comply could lead to delisting. The company, focused on insulin delivery technology, recently announced a $4.68 million public offering and is progressing with its Pivot tubeless insulin patch pump, pending FDA clearance.

Original reporting
Investing.com · Investing.com
Published Jan 1, 2026, 2:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jan 1, 2026, 2:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$MODD
Bearish
medium confidence
Mentioned
$MODD
alphai data visualization · based on Investing.com
Decision brief

The 30-second read

$MODDBearishMed
01

Why it matters

Failure to regain compliance could result in delisting, adversely affecting stock liquidity and investor confidence.

02

Market read

The news is highly relevant for traders holding or considering trading MODD, especially given the imminent compliance deadline.

03

What to watch

Potential for regulatory delays or additional funding needs that could further pressure the stock.

Timing: Immediate to short-term (next 1-3 months)

Background

Modular Medical is a biotech company developing insulin delivery devices, currently facing compliance issues with Nasdaq due to its share price falling below the minimum bid requirement.

Company-level read

Ticker impact

$MODDBearishMedium confidence
Context

The news directly pertains to Modular Medical Inc., affecting its stock outlook.

Expected impact

Potential short-term decline if compliance issues lead to delisting; however, positive developments could mitigate downside.

Evidence & confidence

The low current share price and regulatory risk suggest increased volatility, but upcoming product approvals and funding may provide upside potential.

Market effects

Sector

Potential negative sentiment in the biotech and medical device sectors due to regulatory compliance issues.

Regional

Limited regional impact, primarily affecting US-based biotech stocks.

Global

Minimal

Counterpoint

What could challenge this read

The company's recent funding and FDA progress could lead to a positive turnaround, making current low prices a buying opportunity for long-term investors.

Key entities

  • Regulatory Exchange
    Nasdaq

    The stock exchange requiring Modular Medical to meet minimum bid price standards.

  • Company
    Modular Medical Inc.

    Developer of insulin delivery technology, listed on Nasdaq.

  • Regulatory Agency
    FDA

    U.S. Food and Drug Administration, reviewing the company's Pivot tubeless insulin patch pump.

Read at source← All news

Related articles

AUG 24
$SPCXMed

Billionaire Ron Baron makes $24.9 billion bet on controversial giant

Baron Capital's Q2 13F filing reveals a $24.9 billion stake in SpaceX (SPCX), making it 37.38% of its $66.64 billion portfolio. SPCX closed at $136.97, below Baron's average cost of $170.86. SpaceX reported Q2 2026 revenue of $7.8 billion, a 92% YOY increase, and adjusted EBITDA of $3.5 billion, up 191%. Baron's long-term strategy focuses on growth potential, despite short-term volatility and valuation concerns.

yahoo.com3 min
AUG 24
$RSGMed

Gates-Backed Cascade Sees Opportunity in Republic Services That Half of Wall Street Misses

Cascade Investment, managing Bill Gates' fortune, disclosed buying 654,430 shares of Republic Services (RSG) over four days at prices between $213.70 and $217.18. Cascade now owns 10% of the waste hauler. Republic's Q2 2026 earnings showed 5.3% core price growth, 32.1% EBITDA margin, and raised full-year guidance. Analysts are split, with a consensus target of $245.92, while the stock closed at $220.67.

247wallst.com3 min
AUG 24
$GRMLMed

Greenland Mines Delivers Landmark S-K 1300 Mineral Resource Estimate for Sarfartoq in Greenland; First-Ever Indicated Resource and First Combined Open Pit/Underground Resource for the Critical Nd-Pr M

Greenland Mines Ltd (GRML) announced a landmark S-K 1300 Technical Report for its Sarfartoq Nd-Pr Rare Earths Project in Greenland, prepared by Tetra Tech and GeoSim. The report includes an Indicated Mineral Resource category and a combined open pit/underground resource estimate, marking a first for the project. The resource contains approximately 40,700 tons of neodymium and praseodymium oxide, equivalent to about five years of non-Chinese refined supply in 2025. The company believes Sarfartoq

leaderpost.com2 min
AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min
AUG 24
$CXTLow

Crane NXT (CXT) Could Be 25% Below Fair Value As New President Takes Key Role

Crane NXT (CXT) appointed Jason Lund as President of Crane Payment Innovations and Group President of its Detection and Traceability Technologies segment. The stock trades at $50.20, with a 90-day return of 23.07% but a 1-year return of -18.55%. Analysts suggest it may be 25% undervalued at $66.83, citing growth potential in authentication and cybersecurity, though digital payment shifts and acquisition risks remain.

simplywall.st2 min